Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

Anticancer research - 1 Dec 2011

Schulten Hans-Juergen, Al-Maghrabi Jaudah, Al-Ghamdi Khalid, Salama Sherine, Al-Muhayawi Saad, Chaudhary Adeel, Hamour Osman, Abuzenadah Adel, Gari Mamdooh, Al-Qahtani Mohammed

Abstract excerpt

BACKGROUND: Screening medullary thyroid carcinomas (MTCs) for rearranged during transfection (RET) mutations becomes increasingly important for clinical assessment of the disease. The role of mutations in other genes including RAS (i.e. HRAS, KRAS, and NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-akt murine thymoma viral oncogene homolog 1 (AKT1), and CTNNB1 (β-catenin) is unknown or not fully...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Oncogene Protein p21(ras)

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 22199277

Genes

RET
HRAS
AKT1
BRAF
CTNNB1
KRAS
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.PMID 22199277Read ↗

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.Semantic proximity Read ↗

Molecular advances in medullary thyroid cancer diagnostics.Semantic proximity Read ↗

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.Semantic proximity Read ↗

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Semantic proximity Read ↗

RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.Semantic proximity Read ↗

RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients.Semantic proximity Read ↗

Somatic<i>RAS</i>Mutations Occur in a Large Proportion of Sporadic<i>RET</i>-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonSemantic proximity Read ↗

Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.Semantic proximity Read ↗

Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.Semantic proximity Read ↗

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RETSemantic proximity Read ↗

Not Only RET but NF1 and Chromosomal Instability Are Seen in Young Patients with Sporadic Medullary Thyroid CarcinomaSemantic proximity Read ↗

Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.